Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Chrystal Louis
Celgene Corporation
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
15 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Uc Davis Cancer Center
Sacramento, California, United States
- University of California Los Angeles
Santa Monica, California, United States
- Yale Cancer Center
New Haven, Connecticut, United States
- H. Lee Moffitt Cancer Center and Research Institute University of South Florida
Tampa, Florida, United States
- Northwestern University-Nmdti
Chicago, Illinois, United States
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
- Dana-Farber / Harvard Cancer Institute
Boston, Massachusetts, United States
- John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, United States
- Regional Care Cancer Centers Nj
Morristown, New Jersey, United States
- Levine Cancer Institute
Charlotte, North Carolina, United States
- Oncology Hematology Care, Inc.
Cincinnati, Ohio, United States
- Ohio State Medical Center
Columbus, Ohio, United States
- University of Pennslyvania
Philadelphia, Pennsylvania, United States
- Seattle Cancer Center Alliance
Seattle, Washington, United States
- Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 12 Jan 2015
- Primary completion
- 12 Sept 2018
- Completion
- 12 Sept 2018
- Last update posted
- 31 May 2019
- Registered enrollment
- 114
- Registry id
- NCT02309177
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.